| Literature DB >> 15894331 |
Samuel J Jackson1, Lara T Diemel, Gareth Pryce, David Baker.
Abstract
The current failure of potent immunosuppressive agents to control progressive disease in multiple sclerosis has moved a focus from immunotherapy towards the need for neuroprotection. There is increasing evidence for cannabinoid-mediated control of symptoms, which is being more supported by the underlying biology. However there is accumulating evidence in vitro and in vivo to support the hypothesis that the cannabinoid system can limit the neurodegenerative possesses that drive progressive disease, and may provide a new avenue for disease control.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15894331 DOI： 10.1016/j.jns.2005.03.002
Source DB: PubMed Journal: J Neurol Sci ISSN： 0022-510X Impact factor: 3.181